About
Products
Knolens
KnolScapes
Knolens
Knolens SLR
Knolens
KnolQuest
Knolens
Edge
Knolens
DataNexus
Platform
Solutions
KnolSights
Signup For Free
Voyager Therapeutics Expands Alzheimer's Disease Pipeline with Novel APOE Gene Therapy Program
Voyager Therapeutics announced a new wholly-owned Alzheimer's disease (AD) program targeting apolipoprotein E (APOE), a major genetic risk factor for ...
Copyright © 2025. All rights reserved
About
Terms of Service
Privacy Policy
Home/
KnloSights/
Clinical Trial Updates/
Voyager Therapeutics Expands Alzheimer's Disease Pipeline with Novel APOE Gene Therapy Program